info:eu-repo/semantics/article
Understanding the glioblastoma tumor biology to optimize photodynamic therapy: From molecular to cellular events
Fecha
2020-12Registro en:
Ibarra, Luis Exequiel; Vilchez, Maria Laura; Caverzan, Matias Daniel; Milla Sanabria, Laura Natalia; Understanding the glioblastoma tumor biology to optimize photodynamic therapy: From molecular to cellular events; Wiley-liss, div John Wiley & Sons Inc.; Journal of Neuroscience Research; 99; 4; 12-2020; 1024-1047
0360-4012
CONICET Digital
CONICET
Autor
Ibarra, Luis Exequiel
Vilchez, Maria Laura
Caverzan, Matias Daniel
Milla Sanabria, Laura Natalia
Resumen
Photodynamic therapy (PDT) has recently gained attention as an alternative treatment of malignant gliomas. Glioblastoma (GBM) is the most prevalent within tumors of the central nervous system (CNS). Conventional treatments for this CNS tumor include surgery, radiation, and chemotherapy. Surgery is still being considered as the treatment of choice. Even so, the poor prognosis and/or recurrence of the disease after applying any of these treatments highlight the urgency of exploring new therapies and/or improving existing ones to achieve the definitive eradication of tumor masses and remaining cells. PDT is a therapeutic modality that involves the destruction of tumor cells by reactive oxygen species induced by light, which were previously treated with a photosensitizing agent. However, in recent years, its experimental application has expanded to other effects that could improve overall performance against GBM. In the current review, we revisit the main advances of PDT for GBM management and also, the recent mechanistic insights about cellular and molecular aspects related to tumoral resistance to PDT of GBM.